Abstract
Indications for human papillomavirus vaccination programs are expanding to boys. However, the rationale behind their inclusion is often not clear. Using a Bayesian synthesis framework and assuming equal vaccine coverage in both sexes, we assessed how the incremental number of cancer cases prevented and life-years gained from boys' vaccination are distributed between women, heterosexual men, and men who have sex with men (MSM). Below 60% coverage, at least 50% of the gains from boys' vaccination was attributable to cervical cancer prevention, whereas at 80% coverage, 50% of the gains was attributable to women, 15% to heterosexual men, and 35% to MSM. Above 90% coverage, 85-100% of the gains from boys' vaccination was attributable to anal and oropharyngeal cancer prevention, mainly in MSM. Sex-neutral vaccination can be advocated on grounds of bolstering herd protection to women and directly protecting men, particularly MSM, with the clinical significance of either argument determined by the coverage.
References
Nov 20, 2004·Emerging Infectious Diseases·Al V TairaGillian D Sanders
May 25, 2006·British Journal of Cancer·D H Brewster, L A Bhatti
Jul 22, 2008·BMJ : British Medical Journal·Mark JitW John Edmunds
Jul 2, 2009·Vaccine·Ingrid ZechmeisterUwe Siebert
Oct 10, 2009·BMJ : British Medical Journal·Jane J Kim, Sue J Goldie
Mar 30, 2010·The Journal of Adolescent Health : Official Publication of the Society for Adolescent Medicine·Anil K Chaturvedi
Dec 15, 2010·The Journal of Infectious Diseases·Alan G NyitrayAnna R Giuliano
Feb 3, 2011·British Journal of Cancer·J S HockingJ M L Brotherton
Feb 4, 2011·The New England Journal of Medicine·Anna R GiulianoDalya Guris
Apr 7, 2011·International Journal of Cancer. Journal International Du Cancer·Ann NielsenSusanne K Kjaer
May 6, 2011·Acta Oto-laryngologica·Marie LundbergPetri S Mattila
Jul 12, 2011·The Journal of Infectious Diseases·Marc BrissonMarie-Claude Boily
Aug 6, 2011·Vaccine·Harrell W ChessonLauri E Markowitz
Oct 5, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Anil K ChaturvediMaura L Gillison
Oct 28, 2011·The New England Journal of Medicine·Joel M PalefskyElizabeth I O Garner
Dec 30, 2011·PLoS Medicine·Johannes A BogaardsJacco Wallinga
Jan 21, 2012·BMC Cancer·Susanne HartwigXavier Castellsagué
Aug 31, 2012·Nature·Margaret Stanley
Sep 6, 2012·International Journal of Cancer. Journal International Du Cancer·Michelle M RietbergenRuud H Brakenhoff
Jan 9, 2013·Journal of the National Cancer Institute·Ahmedin JemalBrenda K Edwards
Jul 25, 2013·Human Vaccines & Immunotherapeutics·Yiling JiangXavier Bresse
Mar 22, 2014·PloS One·Emily A BurgerJane J Kim
Jun 27, 2014·BMC Infectious Diseases·Amber L PearsonTony Blakely
Aug 19, 2014·Vaccine·Jean-François LapriseMarc Brisson
Dec 3, 2014·The Lancet Oncology·Cathy NdiayeHelen Trottier
May 20, 2015·BMJ : British Medical Journal·Johannes A BogaardsJohannes Berkhof
Oct 16, 2015·Journal of the National Cancer Institute·Daniel C BeachlerUNKNOWN Costa Rica HPV Vaccine Trial (CVT) Group
Jun 25, 2016·The Lancet Global Health·Laia BruniXavier Castellsagué
Aug 6, 2016·Oral Diseases·G PrueS Warnakulasuriya
Nov 20, 2016·Nature Reviews. Clinical Oncology·Liam Masterson, Matt Lechner
Dec 22, 2016·The Lancet Infectious Diseases·Eric P F ChowChristopher K Fairley
Feb 19, 2017·Cancer Causes & Control : CCC·Scott A McDonaldJohannes A Bogaards
Jun 7, 2017·The Journal of Infectious Diseases·Venetia QendriJohannes Berkhof
Jul 19, 2018·Vaccine·Ellen WolffAdam Roth